SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 4 USD
0.00%
Market Price
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
43.71
43.96
Rango anual
42.45
59.68
Cambio diario
+0.46%
Variación mensual
-12.90%
Variación en los últimos 6 meses
-19.03%
Cambio anual
-18.63%
Cierres anteriores
43.7 4
Open
43.8 5
Mínimo
43.7 1
Máximo
43.9 6
Volumen
57
Ver el calendario completo

Financials

Visión general Informes Estadísticas Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 13 March 2018

Full document

Business Context and Reporting Period

Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2018
Reporting Period: Event-based report regarding a capital raising initiative announced on March 13, 2018.

Key Financial Metrics

This filing does not report historical revenue, profit, cash flow, margins, or existing debt levels. The primary financial metric disclosed is the proposed capital raise:

  • Proposed Offering: $350 million aggregate principal amount of Convertible Senior Notes due 2023.
  • Over-Allotment Option: Initial purchasers may be granted a 30-day option to purchase up to an additional $52.5 million aggregate principal amount.
  • Transaction Structure: Notes to be sold to qualified institutional buyers pursuant to Rule 144A. The Company expects to enter into privately negotiated convertible note hedge and warrant transactions with initial purchasers or affiliates.

Material Changes

The filing discloses a material change in the Company's capital structure plans. On March 13, 2018, the Company announced its intent to offer the Convertible Notes, subject to market and other considerations. This represents a new debt instrument with conversion features, distinct from prior capital structures.

Guidance, Outlook, and Risks

Management Commentary: The Company is disclosing a March 2018 Management Presentation to prospective investors (Exhibit 99.1) to comply with Regulation FD. This presentation contains forward-looking statements regarding plans, strategies, and intentions.

Risks and Contingencies:

  • The Offering is subject to market and other considerations.
  • Forward-looking statements are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
  • The Company undertakes no obligation to update forward-looking statements.

Investor Verification Checklist

  • Verify the final terms and pricing of the $350 million Convertible Senior Notes offering.
  • Confirm whether the 30-day option for an additional $52.5 million was exercised by initial purchasers.
  • Review the specific terms of the privately negotiated convertible note hedge and warrant transactions.
  • Examine the March 2018 Management Presentation (Exhibit 99.1) for detailed financial projections and strategic rationale.
  • Assess the impact of the new debt on the Company's liquidity and leverage ratios post-closing.

Noticias